The objective of this SCOR proposal is to further understand the pathogenesis of pulmonary fibrosis as it relates to IPF. The central hypothesis of this proposal is that the pathogenesis of pulmonary fibrosis is due to """"""""multiple hits"""""""" that perpetuates an imbalance of over-expression of specific pro-inflammatory/proangiogenic/pro-fibrogenic mediators and impaired innate immunity, as compared to anti -inflammatory/anti angiogenic/anti-fibrogenic factors and normal host defense. This paradigm predicts that perpetuation of inflammation, angiogenesis, fibrosis, and susceptibility to recurrent infections beyond what one would expect from immunosuppression alone; ultimately results in impaired innate immunity, susceptibility to infectious disease, and perpetuation of a pro-fibrogenic environment in EPF. This predisposes the IPF patient to more multiple hits"""""""" leading to a vicious cycle of impaired pulmonary function and eventual death. The recognition of these relationships, and to what extent these responses are altered by increased susceptibility to microbes, may yield important clues to more effective prevention and treatment of this process in humans. The SCOR will utilize a multidisciplinary approach to test this central hypothesis. This expertise consists of investigators trained in Pulmonary Diseases, Radiology, Pathology, Cell and Molecular Biology, and Biostatistics. The strengths of this proposal are the investigators, who have productive and collaborative interests in mechanisms related to pulmonary fibrosis. The exceptional institutional resources for biomedical research, the proven commitment to collaborative interaction by both clinicians and basic scientists, and the access to a large population of IPF patients will assure that the studies designed in this proposal will come to fruition.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL067665-01
Application #
6346735
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Musson, Robert
Project Start
2001-09-05
Project End
2006-07-31
Budget Start
2001-09-05
Budget End
2002-07-31
Support Year
1
Fiscal Year
2001
Total Cost
$1,147,213
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Belperio, John A; Keane, Michael P; Lynch 3rd, Joseph P et al. (2006) The role of cytokines during the pathogenesis of ventilator-associated and ventilator-induced lung injury. Semin Respir Crit Care Med 27:350-64
Belperio, John A; Keane, Michael P; Burdick, Marie D et al. (2005) Role of CXCR2/CXCR2 ligands in vascular remodeling during bronchiolitis obliterans syndrome. J Clin Invest 115:1150-62
Pold, Mehis; Zhu, Li X; Sharma, Sherven et al. (2004) Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 64:1853-60
Strieter, Robert M; Belperio, John A; Phillips, Roderick J et al. (2004) Chemokines: angiogenesis and metastases in lung cancer. Novartis Found Symp 256:173-84; discussion 184-8, 259-6
Ma, Bing; Zhu, Zhou; Homer, Robert J et al. (2004) The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling. J Immunol 172:1872-81
Strieter, Robert M; Belperio, John A; Keane, Michael P (2003) CXC chemokines in vascular remodeling related to pulmonary fibrosis. Am J Respir Cell Mol Biol 29:S67-9
Belperio, John A; Keane, Michael P; Burdick, Marie D et al. (2003) Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 171:4844-52
Kao, John; Kobashigawa, Jon; Fishbein, Michael C et al. (2003) Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 107:1958-61
Phillips, Roderick J; Burdick, Marie D; Lutz, Marin et al. (2003) The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167:1676-86
Strieter, Robert M; Belperio, John A; Keane, Michael P (2003) Host innate defenses in the lung: the role of cytokines. Curr Opin Infect Dis 16:193-8

Showing the most recent 10 out of 20 publications